Thalidomide analogs

US7973057B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• P2D, Inc. · US

Inventors

• Nigel H. Greig · Phoenix, US
• Harold W. Holloway · Middle River, US
• Arnold Brossi · Bethesda, US
• Xiaoxiang Zhu · New Brunswick, US
• Tony Giordano · Shreveport, US
• Qian-Sheng Yu · Timonium, US
• William D. Figg · Fairfax, US

Key dates

• Filing date: Sep 17, 2004
• Grant date: Jul 5, 2011
• Expiry date: Oct 24, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.